Réza Elaidi Selected Research

Nivolumab

1/2022	Optimal molecular selection to benefit from nivolumab-ipilimumab in clear-cell renal cell carcinoma.
1/2022	Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Réza Elaidi Research Topics

Disease

4	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 06/2012
1	Heart Failure 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Neoplasms (Cancer) 01/2022
1	Liver Failure 01/2022
1	Massive Hepatic Necrosis 01/2022
1	Thrombotic Microangiopathies 01/2022
1	Digestive System Diseases 01/2022

Drug/Important Bio-Agent (IBA)

2	IpilimumabIBA 01/2022 - 01/2022
2	NivolumabIBA 01/2022 - 01/2022
1	Lipase (Acid Lipase)FDA Link 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Sunitinib (Sutent)FDA Link 01/2022
1	Tyrosine Kinase InhibitorsIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 11/2021

Therapy/Procedure

2	Therapeutics 11/2021 - 06/2012